Welcome to our dedicated page for Establishment Labs Hldgs news (Ticker: ESTA), a resource for investors and traders seeking the latest updates and insights on Establishment Labs Hldgs stock.
News and updates for Establishment Labs Holdings Inc. (NASDAQ: ESTA) center on its role as a global medical device company dedicated to women’s health, particularly in breast aesthetics and reconstruction. Company announcements frequently highlight developments in its Motiva breast implant portfolio, minimally invasive platforms, and reconstruction technologies, as well as financial performance and corporate events.
Investors and clinicians following ESTA news can expect regular coverage of quarterly and annual financial results, including revenue trends, margins, and cash position as disclosed in earnings releases and accompanying conference calls. The company also reports on financing arrangements, such as amendments to its credit agreement and access to additional term loan tranches, through Form 8-K filings and press releases.
Product and clinical news is a recurring theme. Establishment Labs issues updates on regulatory milestones, such as FDA submissions and indications for Motiva implants in breast augmentation and reconstruction. It also shares outcomes from clinical studies, including prospective trials of Mia Femtech, and annual Post-Market Surveillance reports summarizing real-world performance data for Motiva implants across global markets.
Conference participation and investor outreach are another focus of ESTA news. The company announces presentations at major healthcare investment conferences, including events hosted by J.P. Morgan and Jefferies, where its leadership discusses strategy, product platforms, and market opportunities. For users tracking the ESTA stock, this news feed provides a consolidated view of financial disclosures, regulatory updates, clinical evidence, and corporate presentations related to Establishment Labs.
Establishment Labs (NASDAQ: ESTA) will report first-quarter 2026 results before market open on May 6, 2026 and host a conference call at 8:30 am ET. Dial-in and a live/archived webcast are available via the company website. The release reiterates product portfolio, ongoing IRB‑approved pivotal studies, regulatory and manufacturing credentials, and global commercial footprint.
Establishment Labs (NASDAQ: ESTA) announced it has surpassed five million Motiva devices in market across more than 100 countries, reflecting adoption since 2010. The company reported over 25% revenue growth in 2025 and cited US market entry and its minimally invasive Preservé platform as drivers of 2026 momentum.
Preservé is priced about 30% higher than standard Motiva augmentation, and the company operates two ISO13485:2024 and FDA 21 CFR 820 compliant manufacturing facilities in Costa Rica.
Establishment Labs (NASDAQ: ESTA) announced a leadership transition effective March 9, 2026: Raj Denhoy moves from CFO to Senior Vice President, Global Strategy, and Cassandra “Sandra” Harris is appointed Senior Vice President and Chief Financial Officer.
Harris joins with prior CFO experience at Genesco and Tupperware and will lead finance while Denhoy focuses on strategic growth initiatives.
Establishment Labs (NASDAQ: ESTA) reported Q4 2025 revenue $64.6M (+45.2% YoY) and FY2025 revenue $211.1M (+27.2% YoY). Q4 adjusted EBITDA was a positive $5.5M and Q4 net loss from operations narrowed to $3.9M.
The company ended 2025 with $75.6M cash and provided 2026 revenue guidance of $264M–$266M (approximately +25%), with management projecting at least 25% growth in 2027.
Establishment Labs (NASDAQ: ESTA) will present at TD Cowen's 46th Annual Health Care Conference on Monday, March 2, 2026 at 9:10 a.m. ET. CEO Peter Caldini and CFO Raj Denhoy will participate in a fireside chat.
A live webcast and archived replay will be available on the company's investor relations website.
Establishment Labs (NASDAQ: ESTA) will release fourth quarter 2025 financial results before market open on February 24, 2026 and host a conference call at 8:30 am ET that day.
The call accepts U.S./Canada dial-in (877) 407-8037, international +1 (201) 689-8037, conference ID 13758679, and will be live and archived on the company’s Investor Relations website. The company designs Motiva devices and minimally invasive platforms, holds 200+ patent applications, and manufactures in Costa Rica under ISO13485:2016 and FDA 21 CFR 820.
Establishment Labs (NASDAQ: ESTA) announced preliminary unaudited results for Q4 and fiscal 2025. Q4 2025 revenue is expected to be $64.0M–$65.0M, including $17.0M–$17.5M from Motiva sales in the United States. Full-year 2025 revenue is expected to be $210.5M–$211.5M, about 27% growth versus 2024, including $45.4M–$45.9M from U.S. Motiva sales. Year-end 2025 cash is expected to be approximately $75.5M, a $4.8M increase from Q3 2025. Results are preliminary, unaudited, and subject to change. Management reported positive adjusted EBITDA and said it expects to turn free cash flow positive later in 2026 while presenting full audited results on the February earnings call.
Establishment Labs (NASDAQ: ESTA) will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 at 9:45 a.m. PT. CEO Peter Caldini and CFO Raj Denhoy will deliver the presentation.
A live webcast will be available on the company investor relations site and archived webcasts will be posted after the event. The company develops breast aesthetics and reconstruction technologies, with products in over 90 countries and over four million Motiva devices delivered since 2010. Key platforms include Mia Femtech, Preservé, GEM, Motiva Flora tissue expander, and the Zensor RFID/biosensor program; several products are in IRB‑approved pivotal studies. Manufacturing operates from two Costa Rica facilities under ISO13485:2016 and FDA 21 CFR 820 standards.
Establishment Labs (NASDAQ: ESTA) submitted Motiva implants for FDA approval in primary and revision breast reconstruction on December 29, 2025. The submission follows an IDE study across 17 U.S. centers and one Western Europe center that included 274 post-mastectomy reconstruction patients (220 primary, 54 revision) and builds on the company’s prior FDA approval for breast augmentation on September 27, 2024.
The Motiva product family includes SmoothSilk Round and Ergonomix implants, the MRI-conditional Motiva Flora tissue expander cleared in 2023 and in use at over 200 cancer centers, and related platforms (Mia Femtech, Preservé, GEM, Zensor). Since 2010, the company reports over four million Motiva devices delivered globally and more than 60,000 sold in the U.S. since the 2024 augmentation approval.
Establishment Labs (NASDAQ: ESTA) will present at the Jefferies 2025 London Healthcare Conference on Wednesday, November 19, 2025. CEO Peter Caldini and CFO Raj Denhoy will appear in a fireside chat at 8:30 a.m. GMT.
A live webcast will be available on the company's investor relations website and an archived version will be posted after the event. The company develops breast aesthetics and reconstruction solutions, with products in over 90 countries, over 4 million Motiva devices delivered since 2010, a portfolio including Motiva Flora tissue expander, Mia Femtech, Preservé, GEM, Zensor, and the Zenº biosensor, supported by over 200 patent applications and 100 clinical studies. Manufacturing is based in two Costa Rica facilities certified to ISO13485:2016 and FDA 21 CFR 820.